Longeveron (NASDAQ:LGVN) Downgraded to “Sell” Rating by Wall Street Zen

Posted by Francis Steltz on Jul 19th, 2026

Wall Street Zen lowered shares of Longeveron (NASDAQ:LGVN – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday.

LGVN has been the topic of a number of other research reports. Maxim Group cut Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright cut their price target on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Finally, Weiss Ratings cut shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.50.

View Our Latest Stock Analysis on Longeveron

Longeveron Trading Up 1.4%

Shares of NASDAQ:LGVN opened at $0.62 on Friday. The company’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $0.74. Longeveron has a one year low of $0.47 and a one year high of $1.80. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market capitalization of $19.38 million, a PE ratio of -0.55 and a beta of -0.35.

Longeveron (NASDAQ:LGVN – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). Longeveron had a negative return on equity of 202.41% and a negative net margin of 1,844.49%.The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.33 million. On average, equities analysts forecast that Longeveron will post -0.68 EPS for the current fiscal year.

Institutional Trading of Longeveron

An institutional investor recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent reporting period. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.